Cheng Lv, Li Guang-Zheng, Shen Xiang, Xie Yang
Department of Orthopaedics, Ma'anshan People's Hospital Ma'anshan 243000, Anhui, China.
Am J Transl Res. 2025 Aug 15;17(8):6359-6369. doi: 10.62347/AHTO9889. eCollection 2025.
To evaluate the clinical efficacy of combination therapy with celecoxib (CEL) and glucosamine hydrochloride (GH) in patients with knee osteoarthritis (KOA).
A total of 115 KOA patients were retrospectively analyzed and divided into a research group that received CEL combined with GH (n=62), while the control group received CEL alone (n=53). Clinical outcomes, safety, pain severity, knee joint function, quality of life (QoL), bone metabolic markers, and inflammatory indicators were assessed and compared between the groups. Factors associated with treatment efficacy were also analyzed.
The research group showed a significantly higher overall response rate (P=0.018), with no increase in adverse events (P>0.05). Compared to the control group, patients receiving combination therapy experienced greater improvements in pain relief, joint function, QoL, and bone metabolism, along with a more pronounced reduction in inflammatory markers (all P<0.05). Multivariate analysis identified advanced age, alcohol consumption, and smoking history as independent risk factors for poor therapeutic response (all P<0.05).
Combination therapy with CEL and GH provides superior clinical benefits for KOA management. However, its efficacy may be reduced in older patients and those with a history of alcohol use or smoking.
评估塞来昔布（CEL）与盐酸氨基葡萄糖（GH）联合治疗膝骨关节炎（KOA）患者的临床疗效。
回顾性分析115例KOA患者，分为接受CEL联合GH治疗的研究组（n = 62）和单独接受CEL治疗的对照组（n = 53）。评估并比较两组的临床结局、安全性、疼痛严重程度、膝关节功能、生活质量（QoL）、骨代谢标志物和炎症指标。还分析了与治疗效果相关的因素。
研究组的总体有效率显著更高（P = 0.018），不良事件未增加（P>0.05）。与对照组相比，接受联合治疗的患者在疼痛缓解、关节功能、QoL和骨代谢方面有更大改善，炎症标志物降低更明显（均P<0.05）。多因素分析确定高龄、饮酒和吸烟史是治疗反应不佳的独立危险因素（均P<0.05）。
CEL与GH联合治疗为KOA管理提供了更好的临床益处。然而，在老年患者以及有饮酒或吸烟史的患者中其疗效可能会降低。
